Precigen (NASDAQ:PGEN) 주식

PRECIGEN INC

Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen Inc

Pigeon Corp

WIIM

ASLE

AerSale shares are trading lower after the company reported worse-than-expected Q1 sales results.

<p>UGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>) raises FY2025 Adj EPS guidance from $2.75-$3.05 to $3.00-$3.15 vs $3.06 analyst estimate..</p>


News

Guidance

UGI Raises FY2025 Adj EPS Guidance from $2.75-$3.05 to $3.00-$3.15 vs $3.06 Est

<p>MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect MannKind to report an <strong>earnings per share</strong> (EPS) of $0.06.</p>
<p>Investors in MannKind are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.05, leading to a 4.39% drop in the share price the following trading session.</p>
<p>Here's a look at MannKind's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.03</td>
<td>0.03</td>
<td>0.01</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.08</td>
<td>0.06</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>-1.0%</td>
<td>4.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651700_0.png" alt="eps graph" /></p>
<h3>Tracking MannKind's Stock Performance</h3>
<p>Shares of MannKind were trading at $4.78 as of May 06. Over the last 52-week period, shares are up 12.53%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MNKD/earnings"><strong>To track all earnings releases for MannKind visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

MNKD

MannKind's Earnings Outlook

<p>SunOpta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKL#NASDAQ">STKL</a>) raises FY2025 sales outlook from $775.00 million-$805.00 million to $788.00 million-$805.00 million vs $786.69 million estimate.</p>


STKL

SunOpta Raises FY2025 Sales Guidance from $775.00M-$805.00M to $788.00M-$805.00M vs $786.69M Est

<p>Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Arhaus to report an <strong>earnings per share</strong> (EPS) of $0.06.</p>
<p>Investors in Arhaus are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.03, leading to a 14.43% drop in the share price on the subsequent day.</p>
<p>Here's a look at Arhaus's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.12</td>
<td>0.08</td>
<td>0.12</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.15</td>
<td>0.07</td>
<td>0.16</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-14.000000000000002%</td>
<td>-0.0%</td>
<td>5.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651690_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Arhaus were trading at $8.12 as of May 06. Over the last 52-week period, shares are down 46.06%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Insights Shared by Analysts on Arhaus</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Arhaus.</p>
<p>Analysts have provided Arhaus with 6 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $11.25, suggesting a potential 38.55% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Beyond and Williams-Sonoma, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Beyond, with an average 1-year price target of $8.3, suggesting a potential 2.22% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Williams-Sonoma, with an average 1-year price target of $184.38, suggesting a potential 2170.69% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Beyond and Williams-Sonoma, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arhaus</td>
<td>Neutral</td>
<td>0.87%</td>
<td>$138.73M</td>
<td>6.41%</td>
</tr>
<tr>
<td>Beyond</td>
<td>Neutral</td>
<td>-39.38%</td>
<td>$58.13M</td>
<td>-26.08%</td>
</tr>
<tr>
<td>Williams-Sonoma</td>
<td>Neutral</td>
<td>8.04%</td>
<td>$1.11B</td>
<td>19.01%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Arhaus ranks highest in revenue growth among its peers. It ranks lowest in gross profit and return on equity.</p>
<h3>Get to Know Arhaus Better</h3>
<p>Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.</p>
<h3>Arhaus: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Arhaus displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>0.87%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Arhaus's net margin is impressive, surpassing industry averages. With a net margin of <strong>6.14%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Arhaus's ROE excels beyond industry benchmarks, reaching <strong>6.41%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Arhaus's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.76%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Arhaus's debt-to-equity ratio surpasses industry norms, standing at <strong>1.45</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/ARHS/earnings"><strong>To track all earnings releases for Arhaus visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ARHS

A Preview Of Arhaus's Earnings

<p>In the last three months, 8 analysts have published ratings on UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for UL Solutions, presenting an average target of $66.56, a high estimate of $77.00, and a low estimate of $57.00. This upward trend is apparent, with the current average reflecting a 14.27% increase from the previous average price target of $58.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651678_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive UL Solutions is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$63.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Brian Gesuale</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Jason Haas</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Arthur Truslove</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.50</td>
<td>$60.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Stephanie Yee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to UL Solutions. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of UL Solutions compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of UL Solutions's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into UL Solutions's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ULS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on UL Solutions analyst ratings.</strong></a></p>
<h2>Discovering UL Solutions: A Closer Look</h2>
<p>UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.</p>
<h3>UL Solutions: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> UL Solutions displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>8.04%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> UL Solutions's net margin is impressive, surpassing industry averages. With a net margin of <strong>10.96%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> UL Solutions's ROE excels beyond industry benchmarks, reaching <strong>9.12%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> UL Solutions's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.85%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.03</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Expert Outlook: UL Solutions Through The Eyes Of 8 Analysts

<p>Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is preparing to release its quarterly earnings on Thursday, 2025-05-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Trevi Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.12.</p>
<p>The announcement from Trevi Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 3.81% increase in the share price the following trading session.</p>
<p>Here's a look at Trevi Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.11</td>
<td>-0.13</td>
<td>-0.12</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-6.0%</td>
<td>2.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651678_0_0.png" alt="eps graph" /></p>
<h3>Tracking Trevi Therapeutics's Stock Performance</h3>
<p>Shares of Trevi Therapeutics were trading at $6.58 as of May 06. Over the last 52-week period, shares are up 128.08%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/TRVI/earnings"><strong>To track all earnings releases for Trevi Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


TRVI

Earnings Preview For Trevi Therapeutics

<p>BSR REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HOM#TSX">HOM</a>) reported quarterly earnings of $0.22 per share. This is a 8.33 percent decrease over earnings of $0.24 per share from the same period last year.  The company reported $43.48 million in sales this quarter. This is a 3.56 percent increase over sales of $41.98 million the same period last year.</p>


TSX:HOM

BSR REIT Q1 FFO $0.22 Down From $0.24 YoY, Total revenue $43.48M Up From $41.98M YoY

<p>SunOpta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKL#NASDAQ">STKL</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 100 percent increase over earnings of $0.02 per share from the same period last year.  The company reported quarterly sales of $201.60 million which beat the analyst consensus estimate of $194.55 million by 3.62 percent.  This is a 10.26 percent increase over sales of $182.85 million the same period last year.</p>


Earnings Beats

SunOpta Q1 Adj. EPS $0.04 Beats $0.01 Estimate, Sales $201.60M Beat $194.55M Estimate

<p>Ratings for Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $36.25, along with a high estimate of $40.00 and a low estimate of $31.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 21.2%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651669_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Omnicell by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Omnicell. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Omnicell compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Omnicell's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Omnicell's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Omnicell analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>About Omnicell</h2>
<p>Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.</p>
<h3>A Deep Dive into Omnicell's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Omnicell showcased positive performance, achieving a revenue growth rate of <strong>18.56%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Omnicell's net margin excels beyond industry benchmarks, reaching <strong>5.16%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Omnicell's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>1.28%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Omnicell's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.72%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Omnicell's debt-to-equity ratio is below the industry average at <strong>0.31</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OMCL

Beyond The Numbers: 4 Analysts Discuss Omnicell Stock

GRPN

Groupon shares are trading higher after the company reported better-than-expected Q1 financial results.

<p>NN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNBR#NASDAQ">NNBR</a>) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 62.5 percent increase over losses of $(0.08) per share from the same period last year.  The company reported quarterly sales of $105.69 million which missed the analyst consensus estimate of $111.96 million by 5.60 percent.  This is a 12.80 percent decrease over sales of $121.20 million the same period last year.</p>


Earnings Misses

NNBR

NN Q1 Adj. EPS $(0.03), Inline, Sales $105.69M Miss $111.96M Estimate

<p>Analysts' ratings for Dynavax Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $23.4, a high estimate of $33.00, and a low estimate of $10.00. A 2.5% drop is evident in the current average compared to the previous average price target of $24.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651652_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The perception of Dynavax Technologies by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roy Buchanan</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Paul Choi</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dynavax Technologies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dynavax Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dynavax Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Dynavax Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DVAX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Dynavax Technologies analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Dynavax Technologies</h2>
<p>Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.</p>
<h3>Key Indicators: Dynavax Technologies's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Dynavax Technologies showcased positive performance, achieving a revenue growth rate of <strong>29.56%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Dynavax Technologies's net margin is impressive, surpassing industry averages. With a net margin of <strong>9.79%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dynavax Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.1%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Dynavax Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.69%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Dynavax Technologies's debt-to-equity ratio is below the industry average at <strong>0.43</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DVAX

Breaking Down Dynavax Technologies: 5 Analysts Share Their Views

CMTG

Claros Mortgage Trust shares are trading higher after the company reported better-than-expected Q1 sales results.

<p>6 analysts have shared their evaluations of Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $20.0, a high estimate of $27.00, and a low estimate of $16.00. This current average represents a 14.27% decrease from the previous average price target of $23.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651644_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Chemours by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$16.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Chemours. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chemours compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Chemours's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Chemours's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Chemours analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Chemours</h2>
<p>The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.</p>
<h3>Financial Insights: Chemours</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Chemours's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-1.27%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Chemours's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-0.57%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Chemours's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-1.27%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Chemours's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.11%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Chemours's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>7.21</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


6 Analysts Assess Chemours: What You Need To Know

<p>Braemar Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHR#NYSE">BHR</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.36 by 11.11 percent. This is a 4.76 percent decrease over earnings of $0.42 per share from the same period last year.  The company reported quarterly sales of $215.82 million which beat the analyst consensus estimate of $208.35 million by 3.59 percent.  This is a 1.49 percent decrease over sales of $219.08 million the same period last year.</p>


Braemar Hotels & Resorts Q1 FFO $0.40 Beats $0.36 Estimate, Sales $215.82M Beat $208.35M Estimate

<p>13 analysts have shared their evaluations of Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Revolve Gr and provided 12-month price targets. The average target is $25.77, accompanied by a high estimate of $40.00 and a low estimate of $19.00. Highlighting a 12.88% decrease, the current average has fallen from the previous average price target of $29.58. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651631_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Revolve Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Rick Paterson</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Lauren Schenk</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Randal Konik</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Koranda</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$19.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Trevor Young</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Revolve Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Revolve Gr compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Revolve Gr's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Revolve Gr's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RVLV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Revolve Gr analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Revolve Gr Better</h2>
<p>The Revolve Group is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the US, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of unique products from emerging fashion brands with less than $10 million in annual sales.</p>
<h3>Revolve Gr: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Revolve Gr's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>13.95%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Revolve Gr's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.2%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Revolve Gr's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.87%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Revolve Gr's ROA excels beyond industry benchmarks, reaching <strong>1.85%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Revolve Gr's debt-to-equity ratio is below the industry average at <strong>0.09</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RVLV

13 Analysts Have This To Say About Revolve Gr

<p>Analysts' ratings for Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) over the last quarter vary from bullish to bearish, as provided by 20 analysts.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $59.65, a high estimate of $76.00, and a low estimate of $40.00. A decline of 18.95% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746651623_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Celanese among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$59.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$56.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$46.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celanese. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celanese compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Celanese's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Celanese analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Celanese</h2>
<p>Celanese is one of the world's largest producers of acetic acid and its downstream derivative chemicals, which are used in various end markets, including coatings and adhesives. The company is also one of the largest producers of specialty polymers, which are used in the automotive, electronics, medical, building, and consumer end markets. The company also makes cellulose derivatives used in cigarette filters.</p>
<h3>Celanese's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Celanese's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.8%</strong> as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-0.88%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Celanese's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-0.41%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Celanese's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.09%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Celanese's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.52</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Celanese: 20 Analysts Share Their Views

<p>UGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>) reported quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $1.81 by 22.1 percent. This is a 12.18 percent increase over earnings of $1.97 per share from the same period last year.  The company reported quarterly sales of $2.67 billion which missed the analyst consensus estimate of $3.26 billion by 18.22 percent.  This is a 8.07 percent increase over sales of $2.47 billion the same period last year.</p>


UGI Q2 Adj. EPS $2.21 Beats $1.81 Estimate, Sales $2.67B Miss $3.26B Estimate

<p>In the current session, the stock is trading at $80.84, after a <strong>1.42%</strong> increase. Over the past month, <strong>Amphenol Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>)</strong> stock increased by <strong>22.15%</strong>, and in the past year, by <strong>26.70%</strong>. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.</p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1746651618_0.png" alt="Past Year Chart" /></p>

<h3>Comparing Amphenol P/E Against Its Peers</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Compared to the aggregate P/E ratio of the <strong>43.71</strong> in the Electronic Equipment, Instruments &amp; Components industry, Amphenol Inc. has a lower P/E ratio of <strong>38.69</strong>. Shareholders might be inclined to think that  the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1746651618_1.png" alt="Guage" /></p>

<p>In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions. </p>


Intraday Update

Markets

A Look Into Amphenol Inc's Price Over Earnings

Press Releases

Precigen to Participate in the Stifel 2024 Healthcare Conference

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Offerings

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Comments

Precigen

뉴스

파트너 / 기고자

벤징가 글로벌